OBJECTIVES: APPRECIATE is a multinational, retrospective, cross-sectional study of psoriasis patients treated with apremilast in real-world clinical practice. This sub-analysis describes patients’ quality of life (QoL) and satisfaction following apremilast treatment at 16 sites in the UK and Ireland. METHODS: Chronic plaque psoriasis patients who could be contacted 6±1 months after apremilast initiation were enrolled. Assessments included information from medical records, standardized patient-reported outcomes, and patient/physician surveys. Patient results were stratified by baseline Dermatology Life Quality Index (DLQI) category indicating moderate, very large, and extremely large effect on patients’ QoL (DLQI 6‒10 [n=8], 11‒20 [n=51], 21‒30 [n=16], respectively, or missing [n=43]). RESULTS: At apremilast initiation (n=126), mean (SD) age was 48.8 (15.6) years, time since psoriasis diagnosis was 18.8 (14.2) years, and DLQI score was 14.7 (6.2). 85 patients (67%) remained on apremilast at follow-up. Among patients with baseline and follow-up DLQI scores (n=45), mean (SD) DLQI change was −8.9 (8.7); 37% (17/46) achieved DLQI 0/1. In DLQI stratified groups, achievement of DLQI 0/1 was 50% (DLQI 6‒10), 34% (DLQI 11‒20), and 38% (DLQI 21‒30). Patients with baseline DLQI 21‒30 had greatest treatment needs, based on responses on the Patient Needs Questionnaire, and reported greatest benefit on items from the Patient Benefit Questionnaire such as being free of itching (86%), no longer having burning sensations on skin (80%), being healed of all skin defects (73%), or regaining control of the disease (87%). Frequency of patients achieving PBI ≥1 (minimal clinical benefit) was 71%, 83%, and 100%, respectively, for each DLQI category. Treatment Satisfaction Questionnaire for Medication global satisfaction and effectiveness scores were similar regardless of baseline category. CONCLUSIONS: Patients with long-standing chronic plaque psoriasis achieved meaningful improvements in QoL with apremilast regardless of QoL at start of therapy. Confirmation of results is needed due to limited sample.